United Kingdom
Review Article
A Critical Review of Economic Evaluations of Trastuzumab in the Treatment of Early Stage HER2 Positive Breast Cancer
Author(s): Quynh-Nga Thi Nguyen, Hoa Quoc Nguyen and Ciaran Oââ¬â¢NeillQuynh-Nga Thi Nguyen, Hoa Quoc Nguyen and Ciaran O’Neill
Eleven years after Trastuzumab was approved for use in the treatment of early stage human epidermal growth factor receptor positive breast cancer (HER2+) its clinical benefit has been demonstrated in short and long term follow up studies. The cost-effectiveness of the therapy in this context remains the subject of debate with a wide range of Incremental Cost Effectiveness Ratios (ICERs) reported in the literature. While several reviews of the literature have been undertaken these have not provided a critical analysis of the factors that might underlie this heterogeneity. In this review we provide a critical overview of the literature and discuss potential sources of heterogeneity in reported ICERs. We identify gaps in the current literature and provide a rationale for filling these gaps.
.. Read More»
DOI:
10.4172/2472-1042.1000111
Pharmacoeconomics: Open Access received 106 citations as per Google Scholar report